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Abstract
Background
In Vietnam, an estimated 256,000 people are living with HIV, and 58% of HIV-infections
reported are among people who inject drugs (PWID). While antiretroviral therapy (ART) is
widely available in Vietnam, marginalized hard-to-reach male PWID, demonstrate signifi-
cantly reduced and delayed access to ART.
Methods
We investigated the effect of a randomized four-arm multi-level intervention trial on ART ini-
tiation among male PWID. Our analysis was conducted among a subset of trial participants
(n = 136), who were newly diagnosed as HIV-infected, treatment naïve, and eligible for ART
(baseline late diagnosis). The trial arms included: 1, standard of care (HIV testing and
counseling); 2, structural-level intervention (door-to-door communications and community
video screenings); 3, individual-level intervention (counseling plus group support); and 4,
individual-level plus structural-level intervention. In a time-to-event analysis, we used a non-
parametric approach for competing risks to estimate cumulative incidence function (CIF) for
ART initiation (event of interest) by arm and the difference in CIF for each trial arm as
PLOSONE | DOI:10.1371/journal.pone.0161718 August 31, 2016 1 / 14
a11111
OPEN ACCESS
Citation: Zelaya CE, Le Minh N, Lau B, Latkin CA,
Viet Ha T, Minh Quan V, et al. (2016) The Effect of a
Multi-Level Intervention on the Initiation of
Antiretroviral Therapy (ART) among HIV-Infected
Men Who Inject Drugs and Were Diagnosed Late in
Thai Nguyen, Vietnam. PLoS ONE 11(8): e0161718.
doi:10.1371/journal.pone.0161718
Editor: Michael Hoonbae Chung, University of
Washington, UNITED STATES
Received: April 14, 2016
Accepted: August 9, 2016
Published: August 31, 2016
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: Data is available
through the publication of the primary outcomes of
the parent trial published by PLOS ONE: Go VF,
Frangakis C, Minh NL, Latkin C, Ha TV, Mo TT, et al.
Efficacy of a Multi-level Intervention to Reduce
Injecting and Sexual Risk Behaviors among HIV-
Infected People Who Inject Drugs in Vietnam: A Four-
Arm Randomized Controlled Trial. PloS one.2015;10
(5):e0125909.
Funding: This research was funded by both the U.S.
National Institute on Drug Abuse (NIDA) through fund
compared to Arm 1. Follow-up was conducted at 6, 12, 18 and 24 months. Data collection
occurred from 2009 to 2013.
Findings
By 24-months, 61.0% initiated ART, and 30.9% had died prior to ART initiation. In the first 6
months, participants in arm 4 (individual plus community intervention) had a 28% (95% con-
fidence interval (CI): 6–50%) increased probability of initiating ART. Despite increasing cov-
erage of ART in all arms throughout follow-up, participants in arm 4 retained a 31% (95%
CI: 5–56%) increased probability of initiating ART. The individual and community compo-
nents of the intervention were only effective when delivered together.
Conclusions
Marginalized, hard-to-reach men, who do not routinely engage in HIV services, and there-
fore come into care late, may benefit significantly from both individual counseling and group
support, in combination with community-focused stigma reduction, when being referred and
attempting to initiate urgently needed ART.
Introduction
Globally, it is estimated that there are approximately 12.7 million people who inject drugs
(PWID) and approximately 1.7 million of these are HIV-infected.[1] Injection drug use is the
primary driver of HIV epidemics in areas of Eastern Europe, Central and Southeast Asia. Glob-
ally, Vietnam is thought to have the sixth largest population of people who inject drugs
(PWID), with 290,000 people estimated to be injecting drugs in 2009.[2] As of 2014, there are
an estimated 256,000 people living with HIV in Vietnam[3, 4], with PWID accounting for 58%
of infections.[5]
PWID are known to have poorer outcomes when HIV-infected than others,[6] in part due
to diminished and delayed access to ART,[6–13] and therefore need programs that are tailored
for their unique needs. The three interventions deemed effective in reducing transmission of
and treating HIV among PWID are: opioid substitution therapy (OST), antiretroviral therapy
(ART) and needle and syringe programs (NSP).[2]
In Vietnam, the availability of effective services has encouragingly increased in recent years,
with the introduction of NSP in some provinces,[2, 14] and the expansion of Methadone Main-
tenance Therapy (MMT) after a successful pilot started in 2008.[15] The government has com-
mitted to national ART expansion with 37% of people living with HIV receiving ART
nationally in 2014,[2, 16] and has named PWID a priority group in the national plan.[17]
National estimates of ART coverage among PWID are unavailable,[2, 5] however one prior
study in Vietnam observed that PWID were 2.13 times more likely to initiate ART very late
(CD4 count100 cells/mm³) and this late initiation was significantly associated with death.
[18]
Recent evidence has demonstrated the importance of tailoring and rolling out combination
prevention strategies for PWID and other marginalized groups, such as integrating ART and
OST services, and paying particular attention to removing the barriers that these groups face in
accessing and utilizing effective services.[8, 19–21] Expanding ART coverage for PWID is
increasingly an issue of access rather than availability in many settings such as Vietnam.
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Although in many countries injection drug use is stigmatized, in Vietnam, the government
programs to prevent ‘social evils’, such as injection drug use, were purposely linked to HIV
control programs.[22, 23] This fear based approach, likely exacerbated stigma already attached
to injection drug use with HIV-related stigma.[22–24] Pervasive internalized, anticipated, and
experienced stigma related to injection drug use and HIV has proved a major barrier to PWID
initiating ART in Vietnam and other similar settings globally.[21, 25–27] For example, PWID
report lack of ART initiation due to fatalistic attitudes and lack of family and community sup-
port.[25] PWID in some settings including Vietnam, are required to register with authorities
upon seeking treatment,[23, 26] and also perceive and fear that they will not be treated well or
confidentially in health care settings.[21, 23, 25] In addition, many people living with HIV in
Vietnam hold the inaccurate belief that they do not need to be treated until they feel sick.[21]
Therefore many PWID in Vietnam fail to engage in the HIV care continuum until a very late
stage, when symptoms are prevalent and treatment is urgent.[21]
In 2008 our team developed a multi-level prevention intervention, named ACCEPT PROJ-
ECT, to reduce HIV transmission and increase support and coping, among HIV-infected
PWID, by addressing known barriers to prevention and care at the individual and community
level. The main barriers addressed were a) HIV- and drug-related stigma and social isolation,
which prevent disclosure and subsequent adoption of risk reduction strategies, and b) the lack
of in-depth knowledge of HIV disease and effective sexual and injecting risk reduction strate-
gies. The effectiveness of this intervention was evaluated through a randomized controlled trial
among HIV-infected PWID and community members. The trial compared standard HIV vol-
untary counseling and testing (VCT) to an intervention that adds a continuum of psychosocial
support for HIV-infected PWID, and community stigma reduction. The primary and second-
ary outcomes of the trial for the full cohort of HIV infected participants are reported elsewhere,
and include sexual and injecting risk behaviors, disclosure, stigma and social support.[28]
Given the delayed uptake of ART and reported barriers among PWID in Vietnam and else-
where, we investigated the effect of the described multi-level intervention on initiation of ART
among a subset of trial participants who were newly diagnosed as HIV-infected, treatment
naïve, and eligible for therapy at the time of baseline data collection. We conducted a compet-
ing risks analysis as the likelihood of advanced disease and dying was high in this subgroup,
primarily due to clinically late diagnosis and no history of ART use. We hypothesized that both
the individual-level intervention and structural-level community stigma reduction activities
(separately and together) given to HIV-infected participants and their corresponding commu-
nities encouraged initiation in ART.
Methods
Ethics Statement
Written informed consent was obtained from all participants. The study and consent proce-
dures were approved by the ethical review committees at the Johns Hopkins Bloomberg School
of Public Health and the Thai Nguyen Center for Preventive Medicine.
Study Site
The site of this study was the northern province of Thai Nguyen in Vietnam (S1 Fig). Thai
Nguyen has a population of approximately 1,173,000, an estimated population of 5208 PWID.
[29] Substance use is a significant public health problem in Thai Nguyen, consisting primarily
of heroin use like many other provinces in Vietnam. According to national sentinel HIV sur-
veillance data in 2013, HIV prevalence among PWID highest in Thai Nguyen province (34%),
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followed closely by Lai Chai (27.7%) and Hanoi (24%) provinces respectively, in contrast to the
lowest national HIV prevalence estimate of less than 11.6% among PWID since 1997.[4]
Trial Design and Intervention
The trial had a factorial design with four arms: Arm 1—the standard of care (HIV testing and
counseling, HTC); Arm 2—a structural-level community stigma reduction intervention; Arm 3
—a individual-level enhanced posttest counseling and skill-building support groups; and lastly
Arm 4—the standard of care plus both individual-level and structural-level interventions. All
participants received the standard one HIV post-test counseling session. The theories under-
pinning the intervention development and details of the interventions are described elsewhere,
[28] however briefly: The individual-level intervention consisted of two additional HIV post-
test counseling sessions, two skill-building peer support groups, and one optional support ses-
sion with a self-selected support person e.g., family member. These activities aimed to reduce
injecting and sexual risk (through knowledge and skill building), reduce internalized stigma,
and increase disclosure, coping and support among HIV-infected PWID. The structural-level
intervention consisted of two community-based programs: a) two video screenings (which
challenge common misconceptions about HIV transmission and promote positive messages
about HIV-infected individuals) with group discussions in the two months after baseline, and
b) door-to-door communications by community volunteers (six sessions completed with 813
community members over first 12 months after baseline that disseminated HIV information
and answered questions). Both community activities aim to reduce perceived and enacted HIV
and drug related stigma. After the baseline assessment all HIV-infected individuals (irrespec-
tive or trial arm), who where eligible for treatment, were referred to treatment in a nearby hos-
pital by the study physician as part of the assessment procedures. Most of the individual and
structural-level intervention activities were completed in the first 6 months after baseline.
The study design consisted of 32 districts (selected out of the 180 sub-districts in Thai
Nguyen with the largest number of PWID), which were then partitioned into 9 groups (2
groups with 2 districts each, and 7 groups with 4 districts each), so that within each group the
sub-districts were similar in number of drug users and population (S1 Fig). A random half of
the districts in each group were selected to receive the structural-level community stigma
reduction intervention and the remaining districts were selected to receive the standard of care.
The structural-level standard of care was messaging on HIV through village weekly public
loudspeakers and educational pamphlets that were already being provided by community
health stations. Within each district, regardless of structural-level assignment, a random half of
the participants were assigned to receive enhanced posttest counseling and skill building and
the other half received the individual-level standard of care.
Within the districts randomly assigned to the structural-level intervention, the invitations
to video screenings were community-wide. However given that the districts are large (average
population size of 10,000 people) the individuals invited to participate in the 6-sessions with a
community volunteer were selected through a systematic geographic sampling scheme
designed to include individuals who live near PWID, and therefore have the greatest likelihood
of directly or indirectly influencing them.
Participants
The study enrolled male PWID between July 2009 and January 2011. Participants were identi-
fied through a snowball sampling technique and recruited through a team of recruiters, who
were typically former drug users. Inclusion criteria for the index participants were: 1) an HIV-
infected diagnosis confirmed through two parallel rapid HIV tests (Determine: Abbott
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Laboratories, Abbott Park, IL; and Bioline: SD, Toronto, Canada); 2) able and willing to bring
in an injecting network member for screening; 3) male (note: 97% of PWID in Thai Nguyen
are male and female PWID typically have different risk factors.); 4) at least 18 years old; 5) had
sex in the past 6 months; 6) injected drugs in the past 6 months; and 7) planned to live in Thai
Nguyen for the next 2 years. After completion of baseline, all eligible index participants who
agreed were enrolled into the trial as index participants and randomized (n = 455). We
restricted the current analysis to 338 index participants who learnt of their HIV-infected status
for first time after the baseline assessment, to ensure that a) participants analyzed had the same
‘time at risk’ to initiate ART b) had intervention just after learning they were HIV-infected (as
the intervention may have a different effect on those that have been previously living with
HIV), and c) were comparable in terms of history of prior engagement in HIV services. Subse-
quently recruited network partners were not included in this analysis as they were HIV-unin-
fected (as per study design). We then removed the following individuals from the analysis:
those who had missing information on current ART use, or who reported being on ART
regardless of previously stating they did not have a prior known HIV infection (n = 15); with a
CD4 cell count higher than 200 cells/μl (n = 187). Prior to November 2nd 2011 the Vietnamese
Ministry of Health used a CD4 cell count of 200 cells/μl or less as a major criterion for eligibil-
ity to initiate ART. Therefore the study population in this analysis consisted of 136 injection
drug users who had just learned of their HIV-infected status, were eligible for treatment at the
time of baseline data collection, and who had been referred for ART for first time at the base-
line visit.
Assessment Procedures
At the baseline assessment, participants completed a survey self-reporting their prior HIV test-
ing, their HIV status, and any prior use of ART. Participants then completed HIV-testing and
counseling. Those found to be HIV-infected through study rapid tests, had their CD4 cell
count measured, and received a physical exam by our study physician, who also asked the par-
ticipant about prior use of ART. For those who were eligible for treatment, the study physician
gave them a direct referral for treatment to a nearby hospital.
Follow-up occurred at 6, 12, 18 and 24 months. Participants were reimbursed 75,000 Viet-
namese Dong, equivalent to $3.50 USD, at each visit and 5000 Vietnamese Dong ($0.23 USD)
for each kilometer traveled. During the follow-up all index participants completed a survey,
where they self-reported ART use in the prior 6 months. Additionally each index participant
was asked to provide blood specimens to assess the CD4 cell count, and they received a follow-
up physical examination by study physician, where the physician also reported ART use in
prior six months. All participants who missed a visit were contacted. The study team was
informed about deaths through the participants’ family members. We then conducted a verbal
autopsy during which we established date of death. Event of death, was then recorded in first
follow-up visit after death.
Analysis
The data were in discrete time. In this time-to-event analysis the time of origin was baseline,
and termed visit 0 in the analysis. Visits 1, 2, 3, 4 in analysis refer to follow-up visits at 6, 12, 18
and 24 months respectively. We included both a target event and competing event, and indi-
viduals were censored after either event. Mortality is considered a competing event given that it
is impacted by ART initiation (the event of interest), but can also prevent the event of interest
from occurring. ART initiation was the target event, and defined as first report of prior ART
use in past 6 months by study physician. If physician report of ART use was missing, self-report
Initiation of Antiretroviral Therapy and HIV-Infected MenWho Inject Drugs
PLOS ONE | DOI:10.1371/journal.pone.0161718 August 31, 2016 5 / 14
prior ART use in past 6 months was used. Self-report of ART use had a positive predictive
value greater than 92% in all visits. Among the six participants who missed a visit prior to the
visit when they reported ART use for the first time (n = 6), ART initiation was assumed to have
occurred in the 6 months prior to that visit where it was first reported. The competing event
was death, and this was recorded by verbal autopsy. Individuals were censored after occurrence
or target or competing event.
In time-to-event analysis, the occurrence of an event (e.g., mortality) that prevents the event
of interest from happening is a competing risk. As individuals in this study have a non-negligi-
ble probability of death that occurs prior to initiating ART, then analytical methods are
required to account for the competing event as standard survival methods such as the Kaplan-
Meier survival curve will not appropriately estimate the cumulative incidence of ART initia-
tion.[30–34] Therefore, we used a non-parametric approach for competing risks to estimate
cumulative incidence function (CIF)[35, 36] for each arm and the difference in CIF for each
trial arm as compared to Arm 1 –the standard of care for each visit. The CIF for initiation of
ART may be interpreted as the probability of beginning treatment (prior to death, obviously)
by time t. Similarly, the CIF for death is the probability of dying prior to ART initiation by
some time point t. Therefore, the absolute difference in the CIF for initiation of ART (compar-
ing each arm to arm 1) at a specific time (or visit), can be interpreted as a magnitude of the
intervention effect. That is it is the excess of deficit in the probability of initiating ART for an
intervention arm against standard of care. We calculate point wise 95% confidence intervals
(CI) by estimating the variance for the differences in probabilities by summing the estimated
variances of the treatment arm under the assumption that each trial arm are independent sam-
ples. In this analysis, the variance estimation did not account for the study design (i.e., group-
ing districts for randomization), however when accounted for in a similar analyses using the
inferences were not affected.
To elucidate the mechanism by which the intervention was potentially directly influencing
ART initiation or influencing mortality allowing for individuals to remain alive to experience
initiation of ART, we calculated the cause-specific hazards (at each visit) and the estimated
hazard ratios through a pooled log binomial regression, for both the target event (ART initia-
tion) and the competing event (death prior to ART initiation) by trial arm. We allowed for
time-varying relative hazard ratios, however this did not significantly improve model fit
through a likelihood ratio test and therefore a parsimonious model assuming a proportional
hazards assumption was used as a final model. By comparing significance of the ratios for each
outcome (ART initiation and mortality), the cause-specific hazards and hazard ratios provide
information on the “momentary event forces” at a point in time.[37] Thus these estimates pro-
vide information on the magnitude of the force towards a specific event for each trial arm (or
relative to Arm 1).
Results
Description of study population
Of the HIV-infected participants (n = 455), only 26% reported that they were previously aware
of their HIV-infection, 12.9% had previously initiated ART, however 40.8% were found to have
a CD4 cell count equal or lower than 200 cells/μl. Of the newly diagnosed participants who
were eligible for ART (based on CD4 count) in our analysis (n = 136), the mean CD4 cell count
was 110.9 cells/μl and this did not differ by trial arm (Table 1). The mean age was 35 years, and
the majority of participants were either currently married (50.7%) or single (37.5%), and
reported working full time i.e.,> = 30 hours per week (72.1%). To be eligible to participate in
the study all participants had to have injected drugs in the past six months. All participants
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reported that most frequent drug injected was heroin, and approximately a quarter of partici-
pants had previously been in drug treatment centers (camps which are primarily compulsory
with initial period of detoxification and followed by 1–2 years of vocational training), and
37.5% had previously been incarcerated at least once. Despite the low level of ART initiation
observed in HIV-infected at baseline, approximately 30% of participants knew someone who
had or was taking ART. None of the factors described, except ever being incarcerated, were sig-
nificantly different by trial arm.
Events
By the end of our study period, 83 (61.0%) of those newly diagnosed and eligible for treatment
at baseline had initiated ART, and 42 participants were known to have died prior to initiation
of ART (30.9%). Therefore 91.9% of participants had one of two events (either target or com-
peting event), with only 11 participants (8.1%) being censored (i.e., completed study without
an event) or loss to follow-up. Of the participants who reported ART initiation (in past 6
months) throughout follow-up, only 6 missed visits prior to reporting the event of interest (3
missed one visit; 2 missed two visits; 1 missed three visits). Therefore the potential for misclas-
sifying time to event of interest was minimal.
Intervention effect on ART initiation
Fig 1 plots the cumulative incidence curves for ART initiation for each trial arm. Table 2 lists
the time varying absolute difference in cumulative incidence comparing trial arms 2, 3 and 4 to
arm 1, with 95% confidence intervals. These results show that in the first 6 months of follow-
up participants in arm 4 had a 28% increase in probability of initiating ART compared to par-
ticipants in Arm 1. In each arm, the cumulative probability of initiating ART increased every 6
months. However, the inequality between arms remained throughout the follow-up, and actu-
ally increased slightly. At 18-month, a 39% increased probability in initiating ART in arm 4
was observed. By the end of follow-up (24-months) participants in arms 1 to 3 still had a signif-
icantly lower probability of initiating ART (ranging from 0.49 to 0.60) compared to arm 4
Table 1. Baseline characteristics of participants by trial arm (n = 136).
Arm 1 Arm 2 Arm 3 Arm 4 Total
Sample size (N) 26 50 23 37 136
Mean CD4 count, cells/μl (Standard Deviation, SD) 114.3
(53.2)
98.1
(50.0)
127.6
(42.9)
115.7
(39.8)
110.9
(47.5)
Mean Age (SD) 34 (3.9) 35 (5.9) 36 (7.1) 35 (6.3) 34.9 (5.9)
Mean years of education (SD) 8 (3.2) 9 (3.3) 9 (2.7) 9 (2.7) 9 (2.6)
Marital Status (%)
Single (%) (46.2) (38.0) (21.7) (40.5) (37.5)
Currently married(%) (42.3) (46.0) (60.9) (56.8) (50.7)
Widowed/Divorced/ Separated (%) (11.5) (16.0) (17.4) (2.7) (11.8)
Proportion of participants who spent a night on the street, in a park, in an alley, or in an
abandoned building in past 3 months. (%)
(11.54) (16.00) (13.04) (10.81) (13.2)
Proportion working full time, i.e., > = 30 hours per week. (%) (69.2) (70.0) (73.9) (75.7) (72.1)
Proportion ever been in drug treatment (%) (19.2) (32.0) (34.8) (24.3) (27.9)
Ever Incarcerated (prison or jail or detention center)(%)* (53.9) (46.0) (26.1) (21.6) (37.5)
Proportion who knew someone who had taken or who was taking ART. (%) (46.2) (36.0) (13.0) (29.7) (32.4)
*p = 0.02.
doi:10.1371/journal.pone.0161718.t001
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(0.89). There was an overall 31% (confidence interval 5% to 56%) increase in the probability of
ART initiation observed in Arm 4 compared to the standard of care. The cumulative incidence
for ART initiation in arms 1, 2, and 3 did not statistically differ from each other throughout fol-
low-up.
Fig 1. Cumulative incidence function (CIF) for ART initiation by trial arm. Arm 1—Standard of care; Arm 2- Structural-level stigma intervention;
Arm 3—Individual-level intervention; Arm 4—Both structural and individual level intervention.
doi:10.1371/journal.pone.0161718.g001
Table 2. Time varying difference in the non-parametric cumulative incidence function (CIF) by trial arm (arm 1 the reference). Arm 1—Standard of
care; Arm 2- Structural-level stigma intervention; Arm 3—Individual-level HIV intervention; Arm 4—Both structural and individual level interventions.
Visit 1 2 3 4
Lo CI Hi CI Lo CI Hi CI Lo CI Hi CI Lo CI Hi CI
Arm 2 0.06 -0.17 0.30 0.04 -0.21 0.29 0.00 -0.25 0.25 -0.08 -0.33 0.16
Arm 3 0.00 -0.29 0.28 0.07 -0.23 0.38 0.08 -0.23 0.38 0.02 -0.27 0.32
Arm 4 0.28 0.06 0.50 0.30 0.05 0.55 0.39 0.12 0.65 0.31 0.05 0.56
doi:10.1371/journal.pone.0161718.t002
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In order to investigate the possible mechanism of this observed intervention effect, we
examined the cause specific hazards of initiating ART and death (prior to ART initiation) sepa-
rately, for each visit. We also calculated the overall hazard ratios after 24 months of follow-up,
using arm 1 as a reference (see Table 3). In Table 3, we can see that the cause specific hazards
of death did not significantly differ by arm. However, the cause specific hazard of ART initia-
tion was 2.27 times higher in arm 4 (combined individual and structural intervention) as com-
pared to arm 1 (the standard of care). Taken together these data imply that individuals in arm
4 did not solely have a higher probability of initiating ART (Fig 1) by remaining alive to have
the opportunity of treatment initiation.
Discussion
Our results revealed that among HIV-infected men who inject drugs, who have not been previ-
ously diagnosed, and have a CD4 count less than 200 cells/μl and are therefore entering the
HIV care continuum late in Vietnam, the first six months after receiving a positive HIV diag-
nosis is a critical window in time for initiating ART. Providing a comprehensive intervention
which addresses HIV risk, coping, stigma and social support at the individual and structural
level afforded participants in trial arm 4 a significant head start in obtaining effective medical
care (28% increased probability in initiating ART in first 6 months). After this initial period,
the probability of initiating ART treatment increased steadily with time (or visit) in all arms.
However given the head start, participants in arm 4 remained at an advantage, with a 31%
increase in the cumulative probability of initiating ART at 24-months.
None of the socio-economic factors examined, except prior incarceration, differed by trial
arm, therefore we can be relatively confident that randomization balanced arms sufficiently to
minimize confounding. However given that prior incarceration was significantly lower in arm
4 as compared to arm 1, future research should investigate whether stigma and discrimination
associated with a history of incarceration are an additional barrier to care and probability of
initiating ART. Additionally, given that the study was not powered for this sub-analysis, there
could have been a difference in the probability of initiating ART over time in arms 2 and 3, as
compared to arm 1, however we may not have had the sample size to observe this potentially
smaller difference.
We also examined the cause specific hazards to rule out the possibility that the increase in
the probability of initiating ART was purely by keeping participants alive in this sub-popula-
tion with a low CD4 count. Our analysis of the cause specific hazards demonstrated that men
Table 3. Cause specific hazard (by visit), and hazard ratio of either initiating ART (target event), or dying prior to ART initiation (competing event)
by trial arm. Arm 1—Standard of care; Arm 2- Structural-level stigma intervention; Arm 3—Individual-level intervention; Arm 4—Both structural and individ-
ual level intervention.
Event ART Initiation Death (prior to ART initiation)
Cause-specific hazards by visit Visit Visit
1 2 3 4 1 2 3 4
Arm 1 0.35 0.31 0.25 0.29 0.17 0.15 0.17 0.32
Arm 2 0.33 0.29 0.23 0.27 0.27 0.25 0.27 0.46
Arm 3 0.40 0.36 0.29 0.34 0.21 0.20 0.21 0.38
Arm 4 0.62 0.58 0.50 0.55 0.07 0.07 0.07 0.15
Cause-specific hazard ratio, with 95% Confidence Interval (CI) Estimate Lo CI Hi CI Estimate Lo CI Hi CI
Arm 2 0.93 0.48 1.81 1.74 0.77 3.95
Arm 3 1.19 0.56 2.55 1.31 0.49 3.50
Arm 4 2.27 1.19 4.31 0.43 0.13 1.45
doi:10.1371/journal.pone.0161718.t003
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who were in the combined intervention arm and received individual and structural-level inter-
ventions, had 2.3 times higher hazards of initiating ART over 24 months (95% confidence
interval of 1.3 to 7.0), but no higher hazards of survival prior to ART initiation. Therefore, the
mechanism by which some of our participants experienced a higher probability of initiating
ART was likely not through increased opportunity to initiate ART (i.e., being alive), but
through the effects of the interventions they were randomized to receive.
These findings are among the first evidence through randomized study designs and quanti-
tative data to demonstrate that an intervention that addresses social and behavioral factors
such as stigma at both the individual or structural level can effectively improve access to ART.
Therefore these results provide an important contribution to the evidence, and warrant a care-
ful discussion on the mechanism by which this occurred.
To understand how the individual-level enhanced counseling influenced ART initiation
among our participants, we drew upon related studies conducted in PWID. A study of HIV-
infected men who inject drugs in India, reported that lack of family support (e.g., being evicted
from family home) and fear of societal discrimination were a major barrier to accessing treat-
ment given that starting ART would disclose HIV status.[25] In Thai Nguyen, we previously
observed that men felt despair and isolated themselves on learning they were HIV-infected due
to concerns about the additional burden and negative consequences (secondary stigma) for
their family, on top of that already experienced as a result of drug use.[38] However men who
did disclose their status, often found it brought the family closer, as the family rallied to provide
care and support.[38] This and other prior work,[39] suggests that the stigma of drug use is
more pervasive than HIV-related stigma in this community. Due to these prior findings, our
PWID individual counseling sessions focused on encouraging and assisting disclosure and cop-
ing in part through addressing the anticipated primary and secondary stigma and internalized
stigma that men experience. Therefore our counseling (which included family and peer support
sessions) may have increased self-esteem, self-efficacy, disclosure, and immediate family and
peer support thereby reducing depression, and increasing the motivation and ability of an indi-
vidual to seek treatment.
Others have emphasized the importance of generally mobilizing communities and increas-
ing community awareness to reduce stigma and improve utilization of services.[40, 41] These
types of interventions may increase discussions of HIV, substance use, and treatment and lead
to changes in social norms. In our study, the community activities (door-to-door communica-
tions and video screenings) were targeted towards randomly selected neighbors of HIV-
infected PWID, who did not themselves need the services. The success of the community activ-
ities in mobilizing a community to tackle HIV stigma in this setting is not unexpected, given
the success of prior network and community approaches to family planning in Vietnam and
other settings.[42] Door-to-door strategies were conducted by trained members of the commu-
nity, thereby increasing the legitimacy of the messaging and community buy-in. It is also possi-
ble that the community-focused intervention reduced the PWID stigma for the families of
PWIDs, and hence the family was more encouraging for the PWID to seek HIV treatment.
This body of work, and our new findings, are especially relevant to PWID who do not rou-
tinely engage in HIV prevention and care services, and are therefore diagnosed later. More
research is needed to investigate how to expedite HIV testing, and peer referral and stigma
reduction strategies as used in our trial may be beneficial to overcome barriers to testing. How-
ever once tested, this hard-to-reach population also requires assistance beyond a simple referral
to ART treatment. Linkage to care should be supported through a combination of individual
and structural approaches to behavior change.
Our results importantly demonstrate that when the intervention components were given
in isolation (either individual-level enhanced counseling or structural-level community
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stigma reduction program) there was no observed effect on ART initiation. Without com-
munity support and a change in social norms regarding substance use and HIV, already
marginalized and hard-to-reach men in need of treatment, who received counseling
(including family and peer support sessions), still had the barrier of community-level
stigma. This finding is not surprising in the Vietnamese setting where the influence of
community at the commune level is strong (e.g., Women’s Union founded in 1930). The
importance of social norms in influencing behavior has been previously described.[43]
Specifically to PWID, close personal relationships among social networks have previously
been successfully targeted to reduce risk behaviors by changing social norms.[44] Our
results suggest that similar success can be achieved in changing health-seeking behaviors
by targeting close-knit communities. It may be that men received direct encouragement to
seek treatment from their neighbors newly informed on issues related to living with HIV,
and/or felt more accepted and supported by their immediate community and therefore
more motivated to seek treatment themselves. Either way the importance of reducing com-
munity stigma and changing social norms, in conjunction with helping an individual to
cope with a new HIV diagnosis is likely to be key to the successful initiation of necessary
treatment in close-knit communities.
The generalizability of our results may be limited, and replication of results in a more
diverse sample is required. Our study population consisted of men who lived in defined com-
munities, were diagnosed late (CD4 count200 cells/mm³), and were eligible for treatment at
time of diagnosis, and likely symptomatically in evident need of treatment. Further research is
required to assess whether a similar intervention would work on: female PWID; PWID previ-
ously diagnosed HIV-infected but not on treatment; PWID whose community is not defined
by geography; PWID who do not identify with a community; PWID who may be newly HIV-
infected and non-symptomatic; and PWID in other regions of the world. Other limitations of
our findings are that our eligibility criteria for this sub-analysis depended on accurate self-
report of prior knowledge of one’s HIV-infection.
Conclusions
With the ever-looming concerns of government cutbacks in funding for HIV prevention and
care programs, and the potential of The Presidents Emergency Plan for AIDS Relief (PEPFAR)
scale back in Vietnam, this work provides evidence and a framework for effectively improving
access and coverage of ART among PWID. The potential for scale-up and sustainability of this
multi-level approach should now be investigated with implementation science studies that
address barriers to scale-up including need for staff training, lack of leadership commitment
and designs that can evaluate implementation outcomes such as uptake and intervention fidel-
ity. In future research it would be important to examine in detail mechanisms of behavior
change on the community and individual level and whether these changes are sustained after
the intervention. Additionally future investigation into the effect of this multi-level interven-
tion on ART adherence is also warranted. It may also be useful to examine who to target in the
community and the necessary percentage of community members to train. These data may
also support changing recommendations for referring and enrolling HIV-infected patients into
ART early and regardless of symptoms or CD4 count, given the extra time and support that
some individuals may need to successfully initiate and continuously engage in HIV care and
treatment.
In summary, these findings support those who have highlighted the importance of including
behavioral components synergistically at both the individual and community level in combina-
tion prevention strategies.[40, 45]
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